Clinical trials: Schizo-affective Disorder
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Academic-Community EPINET (AC-EPINET)
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features
- Trial name
- AC-EPINET (NCT04497857)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Indiana University
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia, Schizoaffective Disorders
Supervised Treatment of Schizophrenia, a Randomized Controlled Trial.
Patients suffering from Schizophrenia and their families often suffer from poor care because of ignorance about the disorder especially in economically developing countries.
- Trial name
- NCT00392249
- Testing
- Supervised Treatment of Schizophrenia by a family member
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Lady Reading Hospital, Pakistan
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophrenia, Schizoaffective Disorder
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT02566057
- Testing
- PGx testing guided treatment (PGT)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwell Health
Healthy, Schizophrenia
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Brain cells communicate with each other by releasing chemicals called neurotransmitters. In order for brain cells to transfer information, one cell will release a neurotransmitter that will be recognized by a receptor located on…
- Trial name
- NCT00001320
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Brain Circuits in Schizophrenia and Smoking
The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01425684
- Where
- United States
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States
The principle aim of the project is to analyze brain electrical activity and genetic information that will help identify the nature and cause of the disease schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01425671
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Psychosis, Schizophrenia
State Representation in Early Psychosis - Project 4
The purpose of this study is to examine state representation in individuals aged 15-45 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis.
- Conditions
- Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
- Trial name
- STEP (P4) (NCT05664594)
- Testing
- Computerized Cognitive Training
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Schizophrenia
Service User and Staff Views on Digital Remote Monitoring for Psychosis
Psychosis is a severe mental health problem. Symptoms of psychosis include hallucinations (e.g. hearing voices that others cannot hear) and delusions (unusual, often troubling beliefs).
- Conditions
- Psychosis, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT05670197
- Testing
- No intervention. Participants will take part in a qualitative interview
- Where
- 6 sites in United Kingdom
- Volunteers
- 118 people
- Sponsor
- Manchester Academic Health Science Centre
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizoaffective Disorder
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
The aim of this study is to evaluate the effectiveness, safety, and tolerability of metformin treatment in children and adolescents suffering from weight gain secondary to use of atypical antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NCT00391261
- Testing
- Metformin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cambridge Health Alliance
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
Clozapine is the sole AP agent with superiority in treatment refractory schizophrenia, but it also is associated with the greatest risk of weight gain and other metabolic abnormalities.
- Trial name
- NCT02808533
- Testing
- Topiramate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health